<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-12T03:01:35Z</responseDate>
  <request identifier="oai:figshare.com:article/34049233" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34049233</identifier>
        <datestamp>2026-10-01T17:44:32Z</datestamp>
        <setSpec>category_7</setSpec>
        <setSpec>category_8</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_39</setSpec>
        <setSpec>category_46</setSpec>
        <setSpec>category_64</setSpec>
        <setSpec>category_132</setSpec>
        <setSpec>category_134</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_1</setSpec>
        <setSpec>month_year_10_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Immune responses to SARS-CoV-2 in loiasis exposed individuals.&lt;/p&gt;</dc:title>
          <dc:creator>Maximilian Augé Stock (25157980)</dc:creator>
          <dc:creator>Dearie Glory Okwu (18592296)</dc:creator>
          <dc:creator>Ayong More (18592293)</dc:creator>
          <dc:creator>Anna Doralt (25157983)</dc:creator>
          <dc:creator>Rodrigue Bikangui (5851262)</dc:creator>
          <dc:creator>Ismaël Pierrick Mikelet Boussoukou (25157986)</dc:creator>
          <dc:creator>Kirsten Alexandra Eberhardt (7339937)</dc:creator>
          <dc:creator>Maren Sandkuhl (25157989)</dc:creator>
          <dc:creator>Rella Zoleko Manego (9034322)</dc:creator>
          <dc:creator>Ghyslain Mombo-Ngoma (265164)</dc:creator>
          <dc:creator>Matthew McCall (3448769)</dc:creator>
          <dc:creator>Minka Breloer (78015)</dc:creator>
          <dc:creator>Meral Esen (211790)</dc:creator>
          <dc:creator>Marylyn Addo (722007)</dc:creator>
          <dc:creator>Bertrand Lell (224978)</dc:creator>
          <dc:creator>Luzia Veletzky (3831247)</dc:creator>
          <dc:creator>Rafiou Adamou (12419233)</dc:creator>
          <dc:creator>Maria Sophia Mackroth (3309018)</dc:creator>
          <dc:subject>Medicine</dc:subject>
          <dc:subject>Microbiology</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Ecology</dc:subject>
          <dc:subject>Immunology</dc:subject>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Infectious Diseases</dc:subject>
          <dc:subject>Virology</dc:subject>
          <dc:subject>subsequent analysis across</dc:subject>
          <dc:subject>rapid assessment procedure</dc:subject>
          <dc:subject>ogoou &amp;# 233</dc:subject>
          <dc:subject>ngouni &amp;# 233</dc:subject>
          <dc:subject>elevated regulatory cytokines</dc:subject>
          <dc:subject>broader immunological effects</dc:subject>
          <dc:subject>three groups confirmed</dc:subject>
          <dc:subject>specific igg responses</dc:subject>
          <dc:subject>loa loa &lt;/</dc:subject>
          <dc:subject>infection influences antibody</dc:subject>
          <dc:subject>ifn -&amp;# 947</dc:subject>
          <dc:subject>occult participants (&lt;</dc:subject>
          <dc:subject>microfilaremic individuals compared</dc:subject>
          <dc:subject>2 &lt;/ p</dc:subject>
          <dc:subject>loa &lt;/</dc:subject>
          <dc:subject>participants (&lt;</dc:subject>
          <dc:subject>occult disease</dc:subject>
          <dc:subject>immunological assays</dc:subject>
          <dc:subject>p &lt;/</dc:subject>
          <dc:subject>192 participants</dc:subject>
          <dc:subject>microfilaremic compared</dc:subject>
          <dc:subject>γ responses</dc:subject>
          <dc:subject>xlink "&gt;</dc:subject>
          <dc:subject>without evidence</dc:subject>
          <dc:subject>west africa</dc:subject>
          <dc:subject>viral antigens</dc:subject>
          <dc:subject>substantial morbidity</dc:subject>
          <dc:subject>study investigated</dc:subject>
          <dc:subject>skewed responses</dc:subject>
          <dc:subject>sectional study</dc:subject>
          <dc:subject>periurban villages</dc:subject>
          <dc:subject>nucleocapsid proteins</dc:subject>
          <dc:subject>latter defined</dc:subject>
          <dc:subject>including th2</dc:subject>
          <dc:subject>immune modulation</dc:subject>
          <dc:subject>identified using</dc:subject>
          <dc:subject>findings suggest</dc:subject>
          <dc:subject>circulating microfilariae</dc:subject>
          <dc:subject>cell responses</dc:subject>
          <dc:subject>cell hyporesponsiveness</dc:subject>
          <dc:subject>assessed using</dc:subject>
          <dc:subject>90 ).</dc:subject>
          <dc:subject>59 ),</dc:subject>
          <dc:description>&lt;p&gt;Upper panel: comparison of non-microfilaremic (= NM: No sign of active loiasis combined with occult loiasis) versus microfilaremic participants (ML = Microfilaremic loiasis). Lower panel: comparison across three groups (NL = No sign of active loiasis, OL = Occult loiasis, ML = Microfilaremic loiasis). For each panel, Anti-S1-IgG concentrations &lt;b&gt;(a)&lt;/b&gt;, Anti-NCP-IgG ratios &lt;b&gt;(b)&lt;/b&gt;, Interferon-γ concentrations (c) are shown as individual values. The box shows the median and interquartile range (IQR, 25th–75th percentile). Whiskers extend to the most extreme values not exceeding 1.5 × IQR from the first and third quartiles; outliers beyond these limits are plotted as individual points. Intergroup differences were assessed using non-parametric Wilcoxon-rank-sum test (upper panel) or Kruskal-Wallis with subsequent pairwise post hoc comparisons using false discovery rate (FDR) correction (lower panel) and adjusted for the confounders age and sex. &lt;i&gt;P&lt;/i&gt;-values of intergroup comparisons are provided if p &lt; 0.05. * p &lt; 0.05.&lt;/p&gt;</dc:description>
          <dc:date>2026-10-01T17:55:58Z</dc:date>
          <dc:type>Image</dc:type>
          <dc:type>Figure</dc:type>
          <dc:identifier>10.1371/journal.pntd.0014104.g002</dc:identifier>
          <dc:relation>https://figshare.com/articles/figure/_p_Immune_responses_to_SARS-CoV-2_in_loiasis_exposed_individuals_p_/34049233</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
